Solius Labs is bottling sunshine.
What’s happening: The tech maker launched an FDA-cleared personalized UVB light therapy device, supported by a $23M Series A led by Lauder Partners.
Natural flare. Using a skin tone-scanning system to personalize dosing, Solius Pro delivers targeted UVB therapy in a weekly five-minute session. Delivering 12x more biological benefit than the sun with 99% less UV risk, it boosts vitamin D production, mood, energy, cognition, and bone health.
New light. Emphasizing safety, its novel technology prevents UV damage while emitting 50% less radiation than prescription narrow-band UVB devices. Breaking out of the clinical setting, it gained class II medical device status as an OTC product — FDA cleared for supplementary stimulation of vitamin D production and eligible for HSA/FSA purchase.
Feeling golden. 90% of vitamin D comes from sunlight exposure, but ~42% of Americans are deficient. Despite being poorly absorbed and relatively ineffective, US supplement sales topped $1.6B last year.
Beyond vitamin D, consumers are balancing benefits against risks of prolonged UV exposure, taking sunshine into its optimization era, impacting longevity, skin health, and mental health.
Punchline: Providing UV insurance, Solius is betting sunlight becomes a measurable health input, bringing precision dosing to one of nature’s oldest interventions.
